One expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.
The risk of polypharmacy in children is high, and is a sign that modern healthcare is failing, according to one expert.
Stephani Higashi, DC, chief executive of the integrated healthcare practice HEALTH ATLAST, believes that a multiple-disciplinary approach is key.
Higashi
“If we improve our approach to healthcare on an integrated approach the future will hold great things-healthy, happy productive youth leading the future,” Higashi says.
Polypharmacy-which results from patients receiving treatment from multiple doctors, with no coordination of care-is especially dangerous among children because there’s no research to determine the long-term effects prescription medications will have on their bodies, according to Higashi.
“A multiple-disciplinary approach is the necessary paradigm shift,” she says. “The protection is for the patient, but it extends to protect the physicians, specialty providers and pharmacists.”
Higashi reviewed the literature and found that nearly 25% of all children take at least one prescription medication each month, according to a recent CDC study, including opioids, antidepressants and other psychotropic medications.
In addition to increased rates of opioid abuse among America’s youth, there has been a five-fold increase in the number of children prescribed psychostimulant medications, along with a six-fold increase in the number of antipsychotic medications prescribed, according to a recent National Institute of Mental Health blog.
“Managed care executives are some of the most powerful and influential people regarding care, covered care, adjudication of care and determining guidelines for care,” Higashi says. “They literally have the control to determine much of healthcare delivery and the future of our healthcare of our communities. It means we would love for them to have great interest in what is needed to help improve our healthcare and the guidelines of what should or should not be covered and what tests should or should not be done prior to medicating children.”
According to Higashi, most Americans going to a physician expect to receive a prescription when they are seen and are often not satisfied or feel they have been helped if they do not receive the prescription.
“In addition, physicians do not have time and it is easier to simply write a prescription to treat the symptoms,” she says. “Prescriptions also rise due to the increased labeling of symptoms into disease categories which then create categories of drugs to prescribe. Thus the prescription of change your diet, exercise, improve your posture, and get more sleep, and spend more time outdoors with your family and friends, is not actually ever prescribed. Sometimes the best prescription is no prescription.
Next: Five recommendations for executives
Higashi recommends five ways managed care executives can help combat growing polypharmacy rates or child prescription drug use:
“Make sure that blood tests are performed first to ensure there aren’t undiagnosed underlying medical conditions that may be causing the symptoms that a prescriptive drug may otherwise mask causing the condition to be actually untreated,” Higashi says.
Also, make available benefits to children that are available to adults such as massage therapists, acupuncture, physical therapists, nutritionists and the first-line and course of treatment instead of just a prescription, according to Higashi.
“Obviously there are exceptions like emergency appendix rupture, car accident and broken bones that may require medication to control pain,” Higashi says. “But for the majority of visits such as neck pain, back pain, attention problems, depression, anxiety etc something conservative should always be tried first.”
“If we don’t and we continue to allow kids to constantly be on their phone, eat and drink unhealthy, be inactive and turn to prescriptions to quick fix their problems we will have a future of unhealthy, unproductive, unhappy people that may or may not be able to lead the future well,” Higashi says.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More